Response to anti-angiogenesis: An ever changing feature

Research output: Contribution to journalArticlepeer-review


Aims: Anti-angiogenic drugs have gained international approval for the therapy of advanced breast, lung, colo-rectal, kidney and central nervous system cancer. However, the clinical benefit associated with the use of these drugs has been so far limited. Methods: This review discuss the possible rational developments of a new generation anti-angiogenic drugs. Conclusion: Since most of the biological and clinical activity of the currently available generation of anti-angiogenic drugs targets VEGF and its related pathways, it seems relevant to (1) better understand mechanisms of resistance and/or escape from anti-VEGF and (2) identify and validate vascular targets complementary to anti-VEGF.

Original languageEnglish
Issue numberSUPPL. 3
Publication statusPublished - Oct 2011


  • Angiogenesis
  • Anti-angiogenesis
  • Anti-VEGF
  • Endothelial cells
  • VEGF

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Response to anti-angiogenesis: An ever changing feature'. Together they form a unique fingerprint.

Cite this